Gene · 1806
Papers4,420
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 4,420
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A case report of typhlitis during novel use of ropidoxuridine-capecitabine-radiotherapy for treatment-naïve rectal cancer. | Cancer Chemother Pharmacol | 2023 | 37369852 | PubTator, text mining | PubMed |
| Dextran-Coated Iron Oxide Nanoparticles Loaded with 5-Fluorouracil for Drug-Delivery Applications. | Nanomaterials (Basel) | 2023 | 37368241 | PubTator, text mining | PubMed |
| Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States. | Front Pharmacol | 2023 | 37361213 | PubTator, text mining | PubMed |
| Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy. | Clin Pharmacol Ther | 2023 | 37350752 | PubTator, text mining | PubMed |
| Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma. | Oncologist | 2023 | 37339254 | PubTator, text mining | PubMed |
| Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis. | Value Health Reg Issues | 2023 | 37329861 | PubTator, text mining | PubMed |
| Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society. | J Gastroenterol | 2023 | 37329351 | PubTator, text mining | PubMed |
| Recent advances in electrochemical determination of anticancer drug 5-fluorouracil. | ADMET DMPK | 2023 | 37325113 | PubTator, text mining | PubMed |
| A five-cuproptosis-related LncRNA Signature: predicting prognosis, assessing immune function & drug sensitivity in lung squamous cell carcinoma. | J Cancer | 2023 | 37325063 | PubTator, text mining | PubMed |
| Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil. | J Cancer Res Clin Oncol | 2023 | 37318592 | PubTator, text mining | PubMed |
| Folic Acid-Functionalized Albumin/Graphene Oxide Nanocomposite to Simultaneously Deliver Curcumin and 5-Fluorouracil into Human Colorectal Cancer Cells: An In Vitro Study. | Biomed Res Int | 2023 | 37304465 | PubTator, text mining | PubMed |
| Could the tumor-associated microbiota be the new multi-faceted player in the tumor microenvironment? | Front Oncol | 2023 | 37287916 | PubTator, text mining | PubMed |
Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in patients with pancreatic cancer (MultiDom, NCT04263948). | BMJ Open | 2023 | 37286324 | PubTator, text mining | PubMed |
| The pharmacogenomic landscape of an Indigenous Australian population. | Front Pharmacol | 2023 | 37284308 | PubTator, text mining | PubMed |
| Pharmacogenomics in practice: a review and implementation guide. | Front Pharmacol | 2023 | 37274118 | PubTator, text mining | PubMed |
| S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial. | ESMO Open | 2023 | 37270871 | PubTator, text mining | PubMed |
| Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping. | ESMO Open | 2023 | 37267808 | PubTator, text mining | PubMed |
| Editorial: Women in gastrointestinal cancers, volume II: 2022. | Front Oncol | 2023 | 37265801 | PubTator, text mining | PubMed |
| Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm? | Front Pharmacol | 2023 | 37256234 | PubTator, text mining | PubMed |
| Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation. | Front Pharmacol | 2023 | 37256229 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1806/papers?page=25